NCT00027638View on ClinicalTrials.gov

Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

March 31, 2001

Primary Completion Date

December 31, 2003

Study Completion Date

December 31, 2003

Conditions
Gastrointestinal Carcinoid TumorIslet Cell TumorLung CancerNeoplastic Syndrome
Interventions
DRUG

thalidomide

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00027638 - Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter